Guide to this report: The company will definitely increase by 900 million yuan, which will help ease the pressure on the company to expand its business. The participation of actual controllers shows confidence. The participation of actual controllers shows confidence. The leading private enterprises along the Belt and Road are on the uptake, with a target price of 14.93 yuan, increasing holdings. Investment Essentials: Investment advice. Maintaining the forecast that the company's net profit for 2016/17 was 54/760 million yuan, EPS was 0.32/0.43 yuan, and the growth rate was 55%/41% respectively. The target price was 14.93 yuan, corresponding to 47 times PE in 2017, with a space of 37%, and maintained an increase in holdings. There is a definite increase of 900 million dollars over the meeting, and the participation of actual controllers shows confidence. The issue price is 1,041 yuan/share, which is 7% lower than the current price; raising 900 million yuan to make up the flow (600 million yuan) and repay bank loans (300 million yuan) to help the company expand medical PPP business, ease the restrictions on the company's overseas business expansion, and promote the progress of large-scale overseas projects; the actual controller, Mr. Chen Luo and his co-actors invested and subscribed by 50% through the Great Wall of China. The shareholding ratio of Mr. Chen Lue and his co-actors rose from 37.7% to 38.3% after issuance. The sales period was limited to 3 years, demonstrating confidence in the company's future development; the introduction of Beijing Capital Investment Holdings The limited company (the second largest subscriber) is expected to deepen cooperation between the company and Aberdeen Healthcare. Leading private enterprises along the Belt and Road, the order guarantee ratio is high. ① The company's overseas orders increased rapidly in 2016. We estimate that the company signed a new 7-8 billion yuan in 2016 (excluding the 18.8 billion Twin Tower project), doubling the scale of the 4 billion announced overseas orders in 2015. It is estimated that the company has accumulated more than 31 billion overseas orders (winning bids that have not been completed, including the Twin Tower project), with a guaranteed multiplier of 19 times for overseas revenue. ② In December 2016, the company signed a new order for the Twin Towers of Cambodia with a scale of 18.8 billion yuan. Currently, the land for the project has been approved. Construction is expected to begin at the end of March, with a construction period of 5 years. ③ The Belt and Road theme is highly relevant. The company has a high share in Laos, Cambodia, and Kuwait, and orders are mainly distributed in Southeast Asia and the Middle East. risk factors. The fixed increase has not yet been approved; the uncertainty of overseas projects.